Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

A RETROSPECTIVE case series has identified ophthalmic complications in patients using the antidiabetic drugs semaglutide and ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

RELATED: Gynecologist Cautions Women About This "Overlooked" Ozempic Side Effect. Scientists found that Ozempic can weaken ...

Mounjaro (tirzepatide) is a prescription drug used ... Like most drugs, Mounjaro may cause mild or serious side effects. The lists that follow describe some of the more common side effects that ...

The most common side effects include nausea, diarrhea, and decreased appetite. Mounjaro (tirzepatide) is prescribed to help manage blood sugar levels in adults with type 2 diabetes, along with a ...